• Phone: +86 21 63862192
  • Mailbox: info@alphabiopharma.com
  • Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai
  • Beijing: Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing

Introduction

The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China.

About Company

Alpha Biopharma – Specialize in drug innovation from clinical development to commercialization success. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug.

CONTACT US

  • +86 21 63862192
  • Email:info@alphabiopharma.com
  • ShangHai:Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai
  • BeiJing:Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing
苏ICP备2020064883号-1Copyright © 2017-2021 Alpha Biopharma Ltd. All rights reserved.
Follow Us:
Share: